Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Lifeline Scientific (LSI)

  Print      Mail a friend

Monday 28 July, 2008

Lifeline Scientific

New Contract Win

RNS Number : 9402Z
Lifeline Scientific, Inc
28 July 2008

28 July 2008

Lifeline Scientific, Inc('Lifeline' or 'the Company')

New Contract Win

Lifeline division wins contracts to supply LifePort Kidney Transporters 

To Carolina Donor Services

Lifeline Scientific, the medical technology company, announces that its Organ Recovery Systems division has won a contract for the sale of six LifePort(R) Kidney Transporters to Carolina Donor Services ('CDS').  CDS is one of the largest regional organ procurement organisations in the USA and serves a number of transplant centres in North Carolina, United States, including: North Carolina Baptist HospitalDuke UniversityPitt County, and the University of North Carolina.  

The contract, which will also involve the sale of a significant volume of consumables and covers ongoing warranty and maintenance services Based on historical data, it is expected that CDS will LifePort 225-250 kidneys annually. 

David Kravitz, Chief Executive of Lifeline Scientific, said:'This is the fifth significant contract we have announced since the completion of the IPO earlier this year and the subsequent commencement of the full commercial launch of the LifePort Kidney Transporter Not only does LifePort help increase the number of available kidneys but also the quality of those organs, thus improving post-transplant outcomes for patients. LifePort is becoming an important tool in helping to reduce the continuing global shortage of organs for transplantation.

'The continued adoption of our LifePort Kidney Transporter as standard practice by prominent kidney transplant programmes gives us confidence for the future.'



Lifeline Scientific, Inc.
David Kravitz, CEO
Seymour Pierce (Nomad)
+44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs
Financial Dynamics
+44 (0)20 7831 3113
Ben Brewerton / John Dineen



Notes to Editors


The LifePort Kidney Transporter is the Group's lead product. It is designed with the challenges of organ recovery and transport in mind, and provides a sealed, sterile, protected environment where a physiologic chemical solution is gently pumped through the donated kidney at cold temperatures to minimise tissue damage while the organ is outside the body.  Since receiving FDA clearance and CE Marking in 2004, over 250 LifePorts have been employed in pilot programs with leading transplant organizations throughout Europe and North America, preserving more than 12,000 kidneys for clinical transplantation.



Initial clinical outcomes studies have shown that machine preservation improves the quality of a kidney from a cadaveric donor prior to transplantation in comparison to organs statically stored in a traditional cool box. This data demonstrates that machine perfused kidneys are more likely to function immediately after transplantation and remain healthier for longer. Results from an independent investigator driven multi-national, prospective, randomized clinical trial employing LifePort are expected to be published later this year. 

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t